Gross Profit Margin (Quarterly) Chart

View Gross Profit Margin (Quarterly) for RARE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Gross Profit Margin (Quarterly) Chart
Start Trial

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 80.37%
March 31, 2026 72.06%
December 31, 2025 81.75%
September 30, 2025 77.12%
June 30, 2025 81.01%
March 31, 2025 72.97%
December 31, 2024 84.25%
September 30, 2024 78.65%
June 30, 2024 79.50%
March 31, 2024 75.76%
December 31, 2023 90.54%
September 30, 2023 88.79%
June 30, 2023 90.85%
March 31, 2023 83.29%
December 31, 2022 91.12%
September 30, 2022 86.08%
June 30, 2022 86.51%
March 31, 2022 88.13%
December 31, 2021 91.55%
September 30, 2021 90.95%
June 30, 2021 92.81%
Date Value
March 31, 2021 91.39%
December 31, 2020 90.59%
September 30, 2020 93.32%
June 30, 2020 91.92%
March 31, 2020
December 31, 2019 79.56%
September 30, 2019 81.29%
June 30, 2019 88.11%
March 31, 2019 85.85%
December 31, 2018 78.78%
September 30, 2018 60.66%
June 30, 2018 51.38%
March 31, 2018 40.20%
December 31, 2017 -4.18%
September 30, 2017 0.00%
June 30, 2017
March 31, 2017
December 31, 2016 0.00%
September 30, 2016 0.00%
June 30, 2016 0.00%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. 74.71%
Biogen, Inc. 61.37%
BioMarin Pharmaceutical, Inc. 72.27%
Ionis Pharmaceuticals, Inc. 96.13%
Regeneron Pharmaceuticals, Inc. 83.68%

Gross Profit Margin (Quarterly) Related Metrics